MedWatch

A part of Watch Media

As raw material and energy prices rise, so do Coloplast's costs

In Tuesday’s Q1 financial results, medtech company Coloplast’s top and bottom lines reported growth, but increasing energy expenses and wage inflation in Hungary have meant that production costs have also gone up during the first quarter.

Anders Lonning-Skovgaard, EVP and CFO at Coloplast | Photo: Coloplast / PR
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

It is not only Coloplast’s top and bottom lines that have taken leaps in the first quarter of the skewed financial year 2021/2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Foto: Tyrone Siu/Reuters/Ritzau Scanpix

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

  1. Board chair at Coloplast and Lundbeck warns against large pay rises
  2. Ellab slapped with customs fine over US imports
  3. China approves Y-mabs drug
  4. CEO gets "taste of own medicine" by participating in vaccine trial
  5. FDA approves Covid-19 jabs as boosters for infants
  6. Danish agency joins competition authority chorus in criticizing Oticon Medical sale
  7. FDA approves new sensor for insulin pens
  8. Full house for Ambu – all products live up to new EU requirements
  9. EU Commission proposes staggered transition to new medtech requirements after industry warnings
  10. Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
  11. New majority owner makes several board appointments at hearing firm
  12. FDA awards Pfizer's RSV vaccine candidate priority review status
  13. More countries back EU Commission investigation into potential Oticon sale
  14. Nobel Prize winner: "Good research is driven by curiosity"
  15. Forward Pharma's last hope in protracted Biogen battle extinguished

See all

Job

See all jobs

See all jobs